Logo

People in the News: Michael Abrams, Ian MacLachlan

Jan 09, 2014
Premium

Tekmira Pharmaceuticals has appointed Michael Abrams as its chief discovery officer, in charge of drug-discovery efforts at the company.

Abrams previously served as vice president of research and development at CDRD Ventures, and before that was president and CEO of Inimex

Tekmira also said that it has named CSO Ian MacLachlan as executive vice president and chief technical officer in charge of medical countermeasures. In his new role, MacLachlan will handle the expansion of the company's pipeline.

Filed under

Gene Editing, Gene Silencing, & CRISPR
RNAi
Tekmira
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.